

Seroprevalence of Hepatitis A in 7-10 Year-old Children

Seyed Alinaghi Kazemi *¹, MD; Manoochehr Mahram¹, MD; Ali Koosha¹, MD;
Hamid Reza Amirmoghaddami²

1. Department of Pediatrics, Zanjan University of Medical Sciences, IR Iran

2. Clinical Laboratory Sciences, Zanjan University of Medical Sciences, IR Iran

Received: 7/9/06; Revised: 10/12/06; Accepted: 30/12/06

Abstract

Objective: Hepatitis A is one of the most common infections during childhood, especially in developing countries. Regarding the high prevalence of the disease in Iran, this study was performed to detect the rate of the contact of the children of Zanjan/Iran with the virus of hepatitis A (HAV).

Material & Methods: In a cross-sectional study, total anti HAV was assayed by ELISA method in serum samples of 300 children, aged 7-10 years, selected by multistage random sampling. The results were statistically analyzed. 27 children did not agree to participate in the study.

Findings: Out of 273 samples, including 134 males and 139 females, 121 children (44.3%) had serum antibody against Hepatitis A. Of these children, 42%, 45.4% and 45.3% were 7-8, 8-9 and 9-10 years of age, respectively. No significant difference was found among age groups or between sex groups.

Conclusion: According to this study, 44.3% of 7-10 year-old children have had previous contact with hepatitis A virus. This shows a high rate of seronegativity and sensitivity in adult community. Therefore, especially with regard to the high frequency of travels of the people between Iran and neighboring countries, that have high prevalence of disease, revision of national prevention protocol is recommended.

Key Words: Anti-HAV, Children, Hepatitis A, Viral infection

Introduction

Hepatitis A (HA) does not recognize country, state, and international borders^[1], but it is a usually mild and self-limited disease, and rarely causes chronic illness^[2]. The disease in children has good prognosis, with no chronicity^[3]. HA in

children is mostly asymptomatic, and the disease was seldom clinically evident^[4]. For example, in children less than 3 years, more than 80% of infections are clinically silent^[5] but rarely serious complications, such as pleural effusion, are reported^[6]. HA causes approximately half of the

* Correspondence author

Address: Vali-E-Asr Hospital, Zanjan University of Medical Sciences

E-mail: san_kazemi@yahoo.com

cases of viral hepatitis in the United States^[7]. Based on a one-year study in USA, of 270,000 patients of hepatitis A, 159,200 were under 10 years old^[8]. In another study, the rate of seropositivity of hepatitis A in the population of that country was reported to be 60%^[9].

Hepatitis A incidence rates in the United States reached their lowest level in 2002^[7]. In developing nations, most individuals acquire antibody by 5 years of age^[1]. In a study in India, 80% of 5-10 year-old children were seropositive for the disease^[10]. The rate of seropositivity and involvement of the community decreases with increase in socio-economic level and welfare in community^[11,12]. Transmitted maternal antibody can protect an infant completely up to 6 months of age^[13]. Although vaccination against hepatitis A in infancy is less efficient^[14], this performance after 2 years of age has had desirable result^[15].

Anti-HAV can be found in serum from disappearing of the virus in stool, its level reaches maximum in a few months, and will remain measurable up to several years. IgM-antibody remains high only for two months, rarely may be measurable in the next year, and is used to diagnose recent infections. The role of IgG-antibody is to prevent next episode of the infection^[16].

This study was performed on 7-10 year-old children of Zanjan (as a relatively deprived city in Iran), regarding limited studies of this kind in the country. It seems that with the improvement of socio-economic level of the nation, the rate of involvement with the infection is gradually diminishing, but since the disease is accompanied with more complications in older age groups, and with regard to the neighboring countries of low socio-economic and hygienic levels with high prevalence of the infection, the risk of transmission of the disease and occurrence of epidemics in this country should be seriously kept in mind.

Material & Methods

This descriptive study was accomplished from February 2003 through February 2004 in Zanjan

City (North-West of Iran). The sample consisted of 300, 7-10 year-old school children. Using multi-stage randomized method, the children were selected by systematic sampling from 30 primary schools, 10 children from each school. The sample consisted of equal number of both sexes. The minimum sample size for the study was calculated considering $p=80\%$ and $\alpha=95\%$. After two sittings with the schoolmasters and children's parents the aim and potential risk factors of the study were explained to all subjects and their parents before informed consent was obtained. Then, all information needed for the study was registered in questionnaires. Five ml venous blood was collected from each one of the children. The serum from collected blood samples were promptly frozen and kept in micro tubes in -70°C temperature to be examined simultaneously later.

To measure total anti-HAV, we used One-Step Competitive ELISA (Dia-Pro, Milan, Italy) method. Quality control of the kits was performed at a specialized laboratory in Zanjan. Specific antibodies present in serum, compete with specific antibodies linked to HRP (Horse Radish Peroxidase) enzyme to attach to antigens. By adding the enzyme substrate, the strength of the produced color will be reversely proportionate to the quantity of specific anti-HAV antibodies in the serum sample. Sensitivity of this method is 10 IU/L (conformable with WHO standard), specificity and accuracy of the kit were more than 99%.

For statistical analysis of the quantitative and qualitative parameters, we used T-test and K^2 analysis, respectively. An institutional review board in Zanjan University of Medical Sciences approved the study procedures.

Findings

Out of 273 children, including 134 (49%) boys and 139 (51%) girls, 322%, 322% and 356% were in age groups of 7-8, 8-9 and 9-10 years, respectively. There was no significant difference in distribution of samples in age or sex groups. 27 children rejected to participate in the study

On the whole, 121 (443%) cases had high serum level of total antibody against hepatitis A. 425% of girls and 46% of boys were seropositive. Although this showed a little higher prevalence in boys, was not significant statistically. Comparison of age groups for being seropositive is shown in Fig 1.

Discussion

This study showed that about 443% of 7-10 year-old children in Zanjan City had previous contact with hepatitis A virus, with no significant difference in distribution of samples in age or sex groups

There are three similar studies on the prevalence rate of hepatitis A in Iran, which are shown in table 1^[17-19]. The two studies in Tehran indicate the prevalence rates of 33% for children under 5 years and 223%, for those aged 6 months to 15 years^[18, 19]. Different researches show lower prevalence rates in developed communities. For example, 27% of 8–13 year-olds were seropositive in Canada by prior contact with HA virus or immunization^[4]. On the other hand, occurrence of the infection is seen in underdeveloped communities up to 100%^[20].

Involvement with hepatitis A in childhood is directly proportionate to the hygiene level of the community and observance of the rules of health by the people^[16]. A decrease in the prevalence of the disease up to 29%^[21] in Turkey during recent years and unchanged 95% statistical reports in Syria^[22] confirm this assertion.

These reports show a change in age pattern of contamination to the virus. Ehsani et al have recommended revision of prevention protocols of hepatitis A, after contact with this virus in highly contaminated areas in Iran^[19]. Although these results were similar to the results of a study in Istanbul with a prevalence of 29%^[21], had a significant difference with the similar studies in Syria (95%)^[22] and Palestine (937%)^[23].

In our study there was no difference between sexes, but in one recent study in Canada female gender was associated with a higher proportion of anti-HAV IgG positivity^[4]. There is no program for routine hepatitis A vaccination in Iran; this means that 443% of 7-10 year-old children of Zanjan City have had previous contact with Hepatitis A Virus. More than 55% of teenagers in this city would be at risk for infection in case of

Figure-1: Sero-positivity and Sero-negativity in Iranian children




Table 1- Prevalence rates of hepatitis A in Iran:

City	Year	Age Group of Cases	Prevalence Rate
Sari ^[17]	2001	<10 years	879%
Tehran ^[18]	2000	<5 years	223%
Tehran ^[19]	2003	6 months to 15 years	330%

contact with HAV. Changes in immunization policy against hepatitis A should be considered especially with regard to many travels of people between Iran and other countries with high prevalence of disease such as Syria. The probability of an epidemic of the disease in the country should always be kept in mind. To prevent the disease, revision of national prevention protocol, i.e. public vaccination and eventually passive immunization (immune-globulin) is recommended.

Conclusion

According to this study, 443% of 7-10 year-old children of Zanjan City has had previous contact with Hepatitis A Virus.. This shows a high rate of seronegativity and sensitivity in adult community susceptible to infection with regard to the high incidence of travels between Iran and neighboring countries with high prevalence of disease. Therefore, revision of national prevention protocol is recommended.

Acknowledgment

The Deputy of Research Affairs of Zanjan University of Medical Sciences funded this research, for which we are highly grateful. We also have to thank Dr Faranak Sharifi, for her unreserved cooperation and collaboration

References

- Rosenthal P. Hepatitis A: A preventable threat. *J Pediatr Gastroenterol Nutr.* 2002; 35: 595-596.
- Lynda JD, Lynn EG, Maria VK, Denis PR. Calming the panic over hepatitis A. *Nursing.* 2004; 34: 44-47.
- Wei SC. Comparison of clinical manifestations and epidemiology between acute hepatitis A and acute hepatitis E in Taiwan. *J Gastroenterol Hepatol.* 2002; 17: 1187-91.
- Bernard D, Gaston DS, Jan O et al. Nationwide Canadian Study of Hepatitis A Antibody Prevalence Among Children Eight to Thirteen Years Old. *Pediatr Infect Dis J.* 2005; 24: 514-519.
- Charles LT. Hepatitis A in the United States. *Pediatr Infect Dis J.* 2004; 23: 551-552.
- Alhan E. Pleural effusion associated with acute hepatitis A infection. *Pediatr Infect Dis J.* 1999; 18: 1111.
- Hal BJ. The changing picture of hepatitis A in the United States. *Cur Opin Pediatr.* 2004; 16: 89-93.
- Anthony E. Hepatitis A vaccination of infants: Effect of maternal antibody status on antibody persistence and response to a booster dose. *Pediatr Infect Dis J.* 2003; 22: 354-58.
- Sydner DJ. Viral Hepatitis In: Behrman RE, Kleigman RM: *Nelson's Textbook of Pediatrics.* 16th ed. Philadelphia, Saunders. 2000: 768-75
- Kalle A. Changing epidemiology of Hepatitis A antibodies and Hepatitis E in urban and rural India. *JViral Hepatit.* 2001; 8: 93-303.
- Byun KS, Kim JH, Song KJ, et al. Molecular epidemiology of Hepatitis A virus in Korea. *J Gastroenterol Hepatol.* 2001; 16(5): 519-24.
- Lirni G. Seroepidemiology of hepatitis A antibodies among children's hospital staff. *Pediatr Infect Dis J.* 2002; 21: 618-22.

13. Lieberman L. Kinetics of maternal hepatitis A antibody decay in infants. Implications for vaccine use. *Pediatr Infect Dis J* 2002; 21: 347-48.
14. Kanra G. Hepatitis A booster vaccine in children after infant immunization. *Pediatr Infect Dis J*. 2002; 21: 727-30.
15. Sung JJY. Epidemiology of hepatitis A in Asia and experience with the HAV vaccine in Hong Kong. *J Viral Hepatit*. 2000; 7 (Supplement): 27-28.
16. Sherlock S, Dooley J. *Disease of the Liver and Biliary System*. 11th ed. Oxford; Blackwell 2002: 274-81.
17. Shamsizadeh A. Prevalence of hepatitis A in 5-year-old children of Sari. *Med J Ahwaz Univ Med Sci [Persian]*. 2002; 32: 38-40.
18. Rahbari F. Epidemiologic study of hepatitis A in children of Tehran. *Med J Ahwaz Univ Med Sci [Persian]*. 2002; 32: 41-43.
19. Ehsani Ardakani MJ, Jafari Mehr A, Hedaiaati M, et al. Serologic frequency of Hepatitis A in children who referred to Tehran pediatric hospitals in 2002. *J Zanzan Univ Med Sci [Persian]*. 2002; 41(10): 35-8.
20. Berenguer M, Wright TL. Viral hepatitis. In: Feldman M, Friedman LS, Sleisenger MH Sleisenger & Fortran's *Gastrointestinal and Liver Disease*. 7th ed. Philadelphia, Saunders. 2002: 1278.
21. Sidal M, Unuvar E, Oguz F, et al. Age specific seroepidemiology of hepatitis A, B and E infections among children in Istanbul, Turkey. *Eur J Epidemiol*. 2001; 17: 141-44.
22. Antaki N, Kebbewar MK. Hepatitis A seroprevalence rate in Syria. *Trop Doct*. 2000; 30: 99-101.
23. Yassin K, Award R, Tebi A, et al. The epidemiology of hepatitis A infection in Palestine: a universal vaccination program is not yet needed. *Epidemiol Infect J*. 2001; 127:335-339.